肿瘤标志物联合检测对原发性肝癌的诊断价值

目的应用化学发光标记免疫法联合检测五项肿瘤标志物对肝脏疾病的癌变诊断价值进行评估。方法用化学发光标记免疫法对肝癌组56例、肝硬化组40例、肝炎组47例及正常对照组30例的血清甲胎蛋白、癌胚抗原、肿瘤相关糖类抗原CA199、CA125和铁蛋白进行联检。结果原发性肝癌组、肝硬化组和肝炎组AFP、CA199、CA125和SF含量均高于正常对照组（P〈0．05-0．01）；联合检测原发性肝癌的阳性率均高于转移性肝癌（P〈0．05）。结论应用多项指标联检对肝脏疾病的癌变（尤其是原发性肝癌）的检出率可达95％以上，同时对原发性肝癌与转移性肝癌有很好的鉴别作用。

Diagnostic Value of Combined Determination of Tnmor Markers in Patients with Primary Hepatic Carcinoma

Objective To investigate the diagnostic value of combined detection of five item tumor markers in patients with possible malignant change in liver disorders. Methods Serum AFP,CEA,CA199,CA125 and SF levels were determined with chemiluminescence immunoassay in 49 patients with primary liver carcinoma, 7 patients with metastatic liver carcinoma,40 patients with hepatic cirrhosis, 47 patients with HBV hepatitis and 30 cases as controls. Results The serum levels of AFP,CA199,CA125 and SF in patients with primary hepatic cancer and hepatic cirrhosis were all significantly higher than those in controls（P〈 0.01 or 0.05）; The positive rate of combined detection in primary liver cancer was higher than that of metastatic liver cancer（P〈 0.05 ）. Conclusion With combined determination of these five tumor markers,the detection rate of primary hepatic carcinoma can be enhanced to above 95%. Also,differential diagnosis between primary and metastatic hepatic cancers can be facilitated.